Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Apr 30:2022:1721526.
doi: 10.1155/2022/1721526. eCollection 2022.

Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review

Affiliations
Meta-Analysis

Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review

Jingxin Mao et al. Comput Math Methods Med. .

Retraction in

Abstract

Whether TERT promoter mutation is related to more aggressive clinicopathologic features and worse outcomes in papillary thyroid carcinoma patients (PTCs) is still variable and controversial. Our intention was to investigate the risk or prognostic factors that may additionally predict the TERT promoter mutation doable of these lesions and new prevention techniques in PTCs. A total of 2,539 PTC patients with 11.50% TERT mutation have been analyzed using Revman 5.3 software in this study. The PubMed and Embase databases were systematically searched for works published until November 9, 2021. The following variables had been associated with an extended chance of TERT promoter mutation in PTC patients: age < 45 years (MD = 10.93, 95%CI = 7.25-14.61); gender = male (pooled OR = 1.63, 95%CI = 1.17-2.28); tumor size > 1 cm (MD = 0.56, 95%CI = 0.34-0.77); lymph node metastasis (pooled OR = 1.29, 95%CI = 0.93-1.79); vascular invasion (pooled OR = 1.78, 95%CI = 0.83-3.84); extrathyroidal extension (pooled OR = 2.00, 95%CI = 1.32-3.02); distant metastasis (pooled OR = 1.46, 95%CI = 1.04-2.04); advanced TNM stage (pooled OR = 3.19, 95%CI = 2.28-4.45). In addition, multifocality (pooled OR = 0.67, 95%CI = 0.14-3.24) had no affiliation with TERT promoter mutation in PTC patients. Our finding showed that age < 45 years, male, tumor size > 1 cm, lymph node metastasis, vascular invasion, and superior/advanced TNM stage were dangerous elements for TERT promoter mutation of worse effect in PTCs while that multifocality was once negatively correlated. TERT promoter mutation is drastically associated with recurrence and PTC-related mortality.

PubMed Disclaimer

Conflict of interest statement

All authors declare that there has not any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Figures

Figure 1
Figure 1
Flowchart of the selection process on the study.
Figure 2
Figure 2
Forest plots of the relationship between age and TERT mutation in PTC patients.
Figure 3
Figure 3
Forest plots of the relationship between gender and TERT mutation in PTC patients.
Figure 4
Figure 4
Forest plots of the relationship between tumor size and TERT mutation in PTC patients.
Figure 5
Figure 5
Forest plots of the relationship between multifocality and TERT mutation in PTC patients.
Figure 6
Figure 6
Forest plots of the relationship between LNM and TERT mutation in PTC patients.
Figure 7
Figure 7
Forest plots of the relationship between capsular invasion and TERT mutation in PTC patients.
Figure 8
Figure 8
Forest plots of the relationship between ETE and TERT mutation in PTC patients.
Figure 9
Figure 9
Forest plots of the relationship between distant metastasis and TERT mutation in PTC patients.
Figure 10
Figure 10
Forest plots of the relationship between TNM stage and TERT mutation in PTC patients.
Figure 11
Figure 11
Funnel plots for publication bias analysis of the included articles. The OR, MD with 95% CIs for the association between TERT mutation and age, gender, tumor size, multifocality, LNM, capsular invasion, ETE, distant metastasis, and TNM stage, respectively in patients with PTCs. M-H represents Mantel-Haenszel; §IV represents inverse variance.

Similar articles

Cited by

References

    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2017. CA: a Cancer Journal for Clinicians . 2017;67(1):7–30. doi: 10.3322/caac.21387. - DOI - PubMed
    1. Mao Y., Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocrine-Related Cancer . 2016;23(4):313–322. doi: 10.1530/ERC-15-0445. - DOI - PMC - PubMed
    1. Morris L. G., Sikora A. G., Tosteson T. D., Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid . 2013;23(7):885–891. doi: 10.1089/thy.2013.0045. - DOI - PMC - PubMed
    1. Mazeh H., Sippel R. S. Familial nonmedullary thyroid carcinoma. Thyroid . 2013;23(9):1049–1056. doi: 10.1089/thy.2013.0079. - DOI - PubMed
    1. Agrawal N., Akbani R., Aksoy B. A., et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell . 2014;159(3):676–690. doi: 10.1016/j.cell.2014.09.050. - DOI - PMC - PubMed

LinkOut - more resources